297 related articles for article (PubMed ID: 21255410)
21. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
22. IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.
Munn DH; Sharma MD; Johnson TS; Rodriguez P
Cancer Immunol Immunother; 2017 Aug; 66(8):1049-1058. PubMed ID: 28488123
[TBL] [Abstract][Full Text] [Related]
23. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
[TBL] [Abstract][Full Text] [Related]
24. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
26. The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells.
Lepletier A; Lutzky VP; Mittal D; Stannard K; Watkins TS; Ratnatunga CN; Smith C; McGuire HM; Kemp RA; Mukhopadhyay P; Waddell N; Smyth MJ; Dougall WC; Miles JJ
Immunol Cell Biol; 2019 Feb; 97(2):152-164. PubMed ID: 30222899
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention.
Franciszkiewicz K; Le Floc'h A; Jalil A; Vigant F; Robert T; Vergnon I; Mackiewicz A; Benihoud K; Validire P; Chouaib S; Combadière C; Mami-Chouaib F
Cancer Res; 2009 Aug; 69(15):6249-55. PubMed ID: 19638592
[TBL] [Abstract][Full Text] [Related]
28. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.
Sideras K; Biermann K; Yap K; Mancham S; Boor PPC; Hansen BE; Stoop HJA; Peppelenbosch MP; van Eijck CH; Sleijfer S; Kwekkeboom J; Bruno MJ
Int J Cancer; 2017 Aug; 141(3):572-582. PubMed ID: 28470686
[TBL] [Abstract][Full Text] [Related]
29. Tumor-driven evolution of immunosuppressive networks during malignant progression.
Kim R; Emi M; Tanabe K; Arihiro K
Cancer Res; 2006 Jun; 66(11):5527-36. PubMed ID: 16740684
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.
Sørensen RB; Køllgaard T; Andersen RS; van den Berg JH; Svane IM; Straten Pt; Andersen MH
Cancer Res; 2011 Mar; 71(6):2038-44. PubMed ID: 21406395
[TBL] [Abstract][Full Text] [Related]
31. Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice.
Tabbekh M; Franciszkiewicz K; Haouas H; Lécluse Y; Benihoud K; Raman C; Mami-Chouaib F
J Immunol; 2011 Jul; 187(1):102-9. PubMed ID: 21622855
[TBL] [Abstract][Full Text] [Related]
32. Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment.
Nguyen HH; Kim T; Song SY; Park S; Cho HH; Jung SH; Ahn JS; Kim HJ; Lee JJ; Kim HO; Cho JH; Yang DH
Sci Rep; 2016 Jun; 6():28208. PubMed ID: 27306834
[TBL] [Abstract][Full Text] [Related]
33. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
Salih HR; Nüssler V
Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
Holmgaard RB; Zamarin D; Li Y; Gasmi B; Munn DH; Allison JP; Merghoub T; Wolchok JD
Cell Rep; 2015 Oct; 13(2):412-24. PubMed ID: 26411680
[TBL] [Abstract][Full Text] [Related]
35. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
36. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.
Mami-Chouaib F; Echchakir H; Dorothée G; Vergnon I; Chouaib S
Immunol Rev; 2002 Oct; 188():114-21. PubMed ID: 12445285
[TBL] [Abstract][Full Text] [Related]
37. A distinct tolerogenic subset of splenic IDO(+)CD11b(+) dendritic cells from orally tolerized mice is responsible for induction of systemic immune tolerance and suppression of collagen-induced arthritis.
Park MJ; Park KS; Park HS; Cho ML; Hwang SY; Min SY; Park MK; Park SH; Kim HY
Cell Immunol; 2012; 278(1-2):45-54. PubMed ID: 23121975
[TBL] [Abstract][Full Text] [Related]
38. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.
Duechler M; Peczek L; Zuk K; Zalesna I; Jeziorski A; Czyz M
Immunobiology; 2014 Feb; 219(2):158-65. PubMed ID: 24091277
[TBL] [Abstract][Full Text] [Related]
39. Expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
Reschner A; Harlin H; Laven B; Eriksson F; Pisa P; Egevad L
Anal Quant Cytol Histol; 2009 Apr; 31(2):74-82. PubMed ID: 19402383
[TBL] [Abstract][Full Text] [Related]
40. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity.
Gu T; Rowswell-Turner RB; Kilinc MO; Egilmez NK
Cancer Res; 2010 Jan; 70(1):129-38. PubMed ID: 20028855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
